Overview

A Study of Letrozole in the Treatment of Endometrial Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Currently available treatments for endometrial cancer are associated with limited efficacy and significant toxicity. This study will assess the safety and efficacy of letrozole, an aromatase inhibitor, on endometrial cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Collaborator:
Canadian Cancer Trials Group
Treatments:
Letrozole